Novo Nordisk Licenses Parkinson's Program and Exits Cell Therapy as AI Reshapes Pharma R&D
Novo Nordisk gained 24.9% over 30 days while licensing its Parkinson's cell therapy program to Cellular Intelligence and closing its internal cell therapy unit. The moves reflect a broader pharma pivot: outsourcing early-stage biology to AI-native partners while concentrating capital on validated assets like GLP-1. NVIDIA's BioNeMo platform is emerging as central infrastructure for this shift, attracting partnerships from Eli Lilly and Thermo Fisher.
Salvado•